ALLEVYN^o Ag ADHESIVE Antimicrobial Foam Dressing

Smith-Nephew

Helping you get **CLOSER TO ZERO**⁶ human and economic consequence of wounds



ALLEVYN^o Ag ADHESIVE Foam Dressing has tripleaction technology to deliver exudate management to support a moist wound healing environment, with the addition of silver sulfadiazine in the dressing which is effective against micro-organisms in the wound¹⁻³

Features and benefits

Promotes fast healing

ALLEVYN Ag ADHESIVE Dressing maintains a moist wound healing environment which promotes fast healing.^{1,4,5}

Reduces risk of infection

In-vitro ALLEVYN Ag ADHESIVE kills pathogenic organisms found in wounds to reduce the risk of colonisation and infection.⁶

7 day wear time

ALLEVYN Ag ADHESIVE can be left in place for up to seven days (except the sacral area) depending on the nature of the wound and the level of exudate present.²⁻⁴

Secure adhesion to peri-wound tissue

ALLEVYN Ag ADHESIVE Dressing has secure adhesion to help keep the dressing in place without adhering to the wound.^{7,10}

Highly absorbent

ALLEVYN Ag ADHESIVE Dressing has a highly absorbent foam which helps to minimise leakage.^{8,11-13}

Reduces inflammation

In-vitro ALLEVYN Ag ADHESIVE helps reduce bacterial load which is causative of prolonged inflammation and increased matrix metalloproteinase (MMP) levels in the woundd.^{2,14}

Indications

ALLEVYN Ag ADHESIVE is an antimicrobial absorbent dressing for the management, by secondary intention of chronic and acute full thickness, partial thickness or shallow granulating, exuding wounds such as:

- Pressure ulcers
- Venous ulcers
- Diabetic ulcers
- Burns
- Donor sites
- Fungating /malignant wounds
- Surgically dehisced wounds

ALLEVYN Ag ADHESIVE may be used on infected wounds. Where the product is used on infected wounds the wounds should be treated as per local protocol.

ALLEVYN Ag ADHESIVE order references

Sizes	Code	Carton
7.5cm x 7.5cm	66800073	10
10cm x 10cm	66800075	10
12.5cm x 12.5cm	66800078	10
17.5cm x 17.5cm	66800081	10

For detailed product information, including indications for use, contraindications, precautions and warnings, please consult the product's applicable Instructions for Use (IFU) prior to use.

Smith & Nephew Pty Ltd Australia T +61 2 9857 3999 F +61 2 9857 3900

smith-nephew.com/australia

Smith & Nephew Ltd New Zealand T +64 9 820 2840 F +64 9 820 2841 smith-nephew.com/new-zealand

♦Trademark of Smith+Nephew
All Trademarks acknowledged
© 2020 Smith+Nephew
AWM-AWC-25221-anz 1120

References

Smith+Nephew 2009. ALLEVYN Ag ADHESIVE Dressing physical properties. Internal report. DS/09/013/R1. 2. Smith+Nephew 2007. Antimicrobial activity of ALLEVYN Ag ADHESIVE Dressing over 7 days. Internal report. DOF 0703014. 3. Smith+Nephew 2007. ALLEVYN Ag ADHESIVE Dressing silver release testing. Internal report. DOF 0703009.
Smith+Nephew 2008. A multi-centre in-market evaluation of ALLEVYN Ag Dressings. Internal report. SR/CIME/009. 5. Smith+Nephew 2018. Use of moisture vapour permeability (MVP) and moisture vapour transmission rate (MVTR) data to support product claims referring to moist wound healing. Internal statement. EO.AWM.PCSgen.001.v2. 6. Smith+Nephew 2007. Antimicrobial activity of ALLEVYN Ag ADHESIVE Dressing against a broad spectrum of microorganisms. Internal report. DOF 0703007. 7. Martini L, Brandani P, et al. Comparison of two dressings in the management. Journal of Wound Care. 1997;6(10):463-466. 9. Avanzi A, Martinelli M, Accardi S, Giraudi C, Peroli P. Adhesive hydrocullar dressing vs hydrocolloid dressing in the management of 2nd and 3rd degree pus. Poster presented at: Eighth European Conference on Advances in Wound Management; April 26-28, 1998; Madrid, Spain. 10. Smith & Nephew 2015. Product Safety Statement - ALLEVYN ADHESIVE. Internal report. 185. 11. Leonard S, McCluskey P, Long S, Butters V, Winter R, Smith G. An evaluation of ALLEVYN ADHESIVE and NON-ADHESIVE for dom dressings. Wounds *UK*. 2009;5(1):17-26. 12. Smith & Nephew 2009. ALLEVYN ADHESIVE presented at: Nounds *UK*. 2007; Harrogate. 14. Smith+Nephew 2018. A reduced bacterial count reduces the levels of MMP, which are causative of prolonged/chronic inflammation. Internal statement. EO.AWM.PCSgen.003.v1.